Bevacizumab intravitreal injection in the treatment of patients with Central Retinal Vein Occlusion.

Exclusion Criteria16

• Subjects that have used other investigational drug for last 30 days or 5 half-lives (whichever is longer)
• Adequate renal function (glomerular filtration calculated by Cockcroft/Gault formula or measure urine creatinine clearance greater than or equal to 50 mL/minute)
• Diabetic retinopathy with clinically significant macular oedema.
• Retreatment in therapy associated with severe vision loss; unstable heart disease, uncontrolled hypertension; pregnancy, lactation, children
• History of submacular surgery or other surgical intervention for AMD in the study eye, glaucoma filtration surgery, corneal transplant surgery,
• Laser photocoagulation (juxtafoveal or extrafoveal) in the study eye within one month preceding baseline,
• Extracapsular extraction of cataract with phacoemulsification within three months preceding Baseline, or a history of post-operative complications within the last 12 months preceding Baseline in the study eye (uveitis, cyclitis, etcetera),
• History of uncontrolled glaucoma in the study eye (defined as intraocular pressure equal to 25 mmHg despite treatment with anti-glaucoma medication),
• Aphakia with absence of the posterior capsule in the study eye,
• Active intraocular inflammation (grade trace or above) in the study eye,
• Any active infection involving ocular adnexa including infectious conjunctivitis, keratitis, scleritis, endophthalmitis, as well as idiopathic or autoimmune-associated uveitis in either eye,
• Vitreous hemorrhage precluding evaluation of the eye or history of rhegmatogenous retinal detachment or macular hole (Stage 3 or 4) in the study eye,
• Presence of a retinal pigment epithelial tear involving the macula in the study eye, Subfoveal fibrosis or significant atrophy in the study eye
• Women of childbearing potential not using the contraception method(s) specified in this study (specify), as well as women who are breastfeeding
• Known sensitivity to study drug(s) or class of study drug(s)
• Patients with severe medical condition(s) that in the view of the investigator prohibits participation in the study (specify as required)